| Year |
Citation |
Score |
| 2023 |
Haffner M, Ajkunic A, Sayar E, Roudier M, Patel R, Coleman I, Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S, True L, Sperger J, Cheng H, Yu E, ... ... Sawyers C, et al. Assessment of Cell Surface Targets in Metastatic Prostate Cancer: Expression Landscape and Molecular Correlates. Research Square. PMID 38196594 DOI: 10.21203/rs.3.rs-3745991/v1 |
0.304 |
|
| 2023 |
Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Chen X, Socciarelli F, Frankenstein Z, Zou M, Pannellini T, Chen Y, Gardner K, Robinson BD, de Bono J, Abate-Shen C, Rubin MA, ... ... Sawyers CL, et al. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. Biorxiv : the Preprint Server For Biology. PMID 37502956 DOI: 10.1101/2023.07.18.549585 |
0.362 |
|
| 2023 |
Li XF, Selli C, Zhou HL, Cao J, Wu S, Ma RY, Lu Y, Zhang CB, Xun B, Lam AD, Pang XC, Fernando A, Zhang Z, Unciti-Broceta A, Carragher NO, ... ... Sawyers C, et al. Macrophages promote anti-androgen resistance in prostate cancer bone disease. The Journal of Experimental Medicine. 220. PMID 36749798 DOI: 10.1084/jem.20221007 |
0.349 |
|
| 2022 |
Chan JM, Zaidi S, Love JR, Zhao JL, Setty M, Wadosky KM, Gopalan A, Choo ZN, Persad S, Choi J, LaClair J, Lawrence KE, Chaudhary O, Xu T, Masilionis I, ... ... Sawyers CL, et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science (New York, N.Y.). eabn0478. PMID 35981096 DOI: 10.1126/science.abn0478 |
0.374 |
|
| 2021 |
Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, Lee C, Haywood S, Chen X, Chang Q, Xu G, Chen HA, de Stanchina E, Sawyers C, Rosen N, et al. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nature Communications. 12: 5053. PMID 34417459 DOI: 10.1038/s41467-021-25341-9 |
0.374 |
|
| 2021 |
Feng W, Cao Z, Lim PX, Zhao H, Luo H, Mao N, Lee YS, Rivera AA, Choi D, Wu C, Han T, Romero R, de Stanchina E, Carver BS, Wang Q, ... ... Sawyers CL, et al. Rapid interrogation of cancer cell of origin through CRISPR editing. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34353917 DOI: 10.1073/pnas.2110344118 |
0.77 |
|
| 2020 |
Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, ... ... Sawyers CL, et al. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 4. PMID 33015525 DOI: 10.1200/PO.20.00097 |
0.334 |
|
| 2020 |
Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, ... ... Sawyers CL, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. PMID 32679108 DOI: 10.1016/J.Ccell.2020.06.005 |
0.683 |
|
| 2020 |
Leibold J, Ruscetti M, Cao Z, Ho YJ, Baslan T, Zou M, Abida W, Feucht J, Han T, Barriga FM, Tsanov KM, Zamechek L, Kulick A, Amor C, Tian S, ... ... Sawyers CL, et al. Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis. Cancer Discovery. PMID 32376773 DOI: 10.1158/2159-8290.Cd-19-1242 |
0.33 |
|
| 2020 |
Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, ... ... Sawyers CL, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. PMID 32220301 DOI: 10.1016/J.Ccell.2020.03.001 |
0.644 |
|
| 2020 |
Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Triparna S, Rudin CM. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nature Reviews. Clinical Oncology. PMID 32152485 DOI: 10.1038/s41571-020-0340-z |
0.339 |
|
| 2020 |
Mao N, Gao D, Hu W, Gadal S, Hieronymus H, Wang S, Lee YS, Sullivan P, Zhang Z, Choi D, Rosen N, Sawyers CL, Gopalan A, Chen Y, Carver BS. Oncogenic ERG represses PI3K signaling through down-regulation of IRS2. Cancer Research. PMID 32015092 DOI: 10.1158/0008-5472.Can-19-1394 |
0.326 |
|
| 2019 |
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, ... ... Sawyers CL, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31363002 DOI: 10.1158/1078-0432.Ccr-19-1423 |
0.338 |
|
| 2019 |
Zhu B, Cao A, Li J, Young J, Wong J, Ashraf S, Bierzynska A, Menon MC, Hou S, Sawyers C, Campbell KN, Saleem MA, He JC, Hildebrandt F, D'Agati VD, et al. Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2. Kidney International. PMID 31171376 DOI: 10.1016/J.Kint.2019.03.016 |
0.352 |
|
| 2019 |
Lee E, Wongvipat J, Choi D, Wang P, Lee YS, Zheng D, Watson PA, Gopalan A, Sawyers CL. amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance. Elife. 8. PMID 30644358 DOI: 10.7554/Elife.41913 |
0.339 |
|
| 2019 |
Kubler K, Karlic R, Haradhvala NJ, Ha K, Kim J, Kuzman M, Jiao W, Gakkhar S, Mouw KW, Braunstein LZ, Elemento O, Biankin AV, Rooman I, Miller M, Nogiec CD, ... ... Sawyers C, et al. Abstract 2727: The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin Cancer Research. 79: 2727-2727. DOI: 10.1158/1538-7445.Am2019-2727 |
0.39 |
|
| 2019 |
Zhang Z, Karthaus W, Mota JM, Mu P, Wu C, Abida W, Linton E, Lee YS, Lee E, Mao N, Adams E, Choi D, Rathkopf DE, Carver B, Gopalan A, ... ... Sawyers C, et al. Abstract 111: Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer Cancer Research. 79: 111-111. DOI: 10.1158/1538-7445.Am2019-111 |
0.714 |
|
| 2018 |
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, ... ... Sawyers CL, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications. 9: 2404. PMID 29921838 DOI: 10.1038/s41467-018-04495-z |
0.322 |
|
| 2018 |
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, ... ... Sawyers CL, et al. The long tail of oncogenic drivers in prostate cancer. Nature Genetics. PMID 29610475 DOI: 10.1038/S41588-018-0078-Z |
0.328 |
|
| 2017 |
Hieronymus H, Iaquinta PJ, Wongvipat J, Gopalan A, Murali R, Mao N, Carver BS, Sawyers CL. Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nature Communications. 8: 1081. PMID 29057879 DOI: 10.1038/S41467-017-01198-9 |
0.334 |
|
| 2017 |
Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 6. PMID 28891793 DOI: 10.7554/Elife.27861 |
0.359 |
|
| 2017 |
Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y, ... ... Sawyers CL, et al. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. PMID 28614298 DOI: 10.1038/Nature22820 |
0.341 |
|
| 2017 |
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, ... ... Sawyers CL, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (New York, N.Y.). 355: 84-88. PMID 28059768 DOI: 10.1126/Science.Aah4307 |
0.693 |
|
| 2017 |
Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science (New York, N.Y.). 355: 78-83. PMID 28059767 DOI: 10.1126/Science.Aah4199 |
0.682 |
|
| 2016 |
Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers CL, Elashoff D, et al. Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Reports. 17: 2596-2606. PMID 27926864 DOI: 10.1016/J.Celrep.2016.11.010 |
0.653 |
|
| 2016 |
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, ... ... Sawyers C, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England Journal of Medicine. PMID 27433846 DOI: 10.1056/Nejmoa1603144 |
0.391 |
|
| 2016 |
Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y, Clevers H. Organoid culture systems for prostate epithelial and cancer tissue. Nature Protocols. 11: 347-58. PMID 26797458 DOI: 10.1038/Nprot.2016.006 |
0.603 |
|
| 2016 |
Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ. Applying 89Zr-transferrin to study the pharmacology of inhibitors to BET bromodomain containing proteins. Molecular Pharmaceutics. PMID 26725682 DOI: 10.1021/Acs.Molpharmaceut.5B00882 |
0.315 |
|
| 2016 |
Bose R, Abida W, Iaquinta P, Karthaus W, Armenia J, Wongvipat J, Doran M, Hieronymus H, Philip W, Liang Y, Schultz N, Sawyers CL. Investigation of a frequently mutated transcriptional repressor in prostate cancer, in particular its role in modulating androgen signaling and its effects on TMPRSS2-ERG dependent tumor maintenance. Journal of Clinical Oncology. 34: 274-274. DOI: 10.1200/Jco.2016.34.2_Suppl.274 |
0.334 |
|
| 2016 |
Wise D, Louw J, Krupa R, Schreiber NA, Sawyers CL, Dittamore RV, Scher HI. Detection of glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) from patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 5046-5046. DOI: 10.1200/JCO.2016.34.15_SUPPL.5046 |
0.318 |
|
| 2016 |
Agarwal S, Hynes P, Lake R, Fang L, Tillman H, Beshiri M, Jansson K, Karthaus W, Iaquinta P, Sawyers C, Kelly K. Abstract LB-276: The identification and characterization of prostate adenocarcinoma tumor initiating cells Cancer Research. 72. DOI: 10.1158/1538-7445.Am2016-Lb-276 |
0.393 |
|
| 2016 |
Bose R, Abida W, Karthaus W, Armenia J, Iaquinta P, Wongvipat J, Doran M, Hieronymus H, Watson P, Sullivan P, Liang Y, Schultz N, Sawyers C. Abstract LB-018: Loss of function mutations of an ETS repressor expand the ETS positive subset of prostate cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-018 |
0.445 |
|
| 2016 |
Vis DJ, Lewin J, Siu L, Liao R, Zenklusen JC, Calvo F, Szepessy E, Vivancos A, Wirta V, Madhavan S, Park K, Tan D, Laskin J, Brammer M, Dias-Neto E, ... ... Sawyers C, et al. Abstract 5287: Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH): Cancer Research. 76: 5287-5287. DOI: 10.1158/1538-7445.Am2016-5287 |
0.304 |
|
| 2016 |
Shah N, Arora V, Karthaus W, Wongvipat J, Zheng D, Sawyers C. A distinct epigenetic state sensitizes enzalutamide-resistant prostate cancer cells to BET bromodomain inhibition European Journal of Cancer. 61: S9. DOI: 10.1016/S0959-8049(16)61020-1 |
0.32 |
|
| 2015 |
Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature Reviews. Cancer. PMID 26563462 DOI: 10.1038/nrc4016 |
0.332 |
|
| 2015 |
Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Research. PMID 26432404 DOI: 10.1158/0008-5472.Can-15-0892 |
0.316 |
|
| 2015 |
Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL. Identification of an oncogenic RAB protein. Science (New York, N.Y.). 350: 211-7. PMID 26338797 DOI: 10.1126/Science.Aaa4903 |
0.351 |
|
| 2015 |
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, ... ... Sawyers CL, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 161: 1215-28. PMID 26000489 DOI: 10.1016/J.Cell.2015.05.001 |
0.615 |
|
| 2015 |
Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell. 27: 109-22. PMID 25544636 DOI: 10.1016/j.ccell.2014.11.008 |
0.332 |
|
| 2015 |
Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers CL, et al. Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Molecular Cancer Therapeutics. 14: 278-88. PMID 25381262 DOI: 10.1158/1535-7163.Mct-14-0542-T |
0.644 |
|
| 2015 |
Mu P, Cao Z, Hoover E, Wongvipat J, Huang C, Karthaus W, Abida W, Stanchina ED, Sawyers C. Abstract LB-056: TP53 and RB1 alterations promote reprogramming and antiandrogen resistance in advanced prostate cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-056 |
0.72 |
|
| 2014 |
Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, ... ... Sawyers CL, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 159: 176-87. PMID 25201530 DOI: 10.1016/J.Cell.2014.08.016 |
0.638 |
|
| 2014 |
Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RG, Cuppen E, Chen Y, Sawyers CL, Clevers HC. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 159: 163-75. PMID 25201529 DOI: 10.1016/j.cell.2014.08.017 |
0.592 |
|
| 2014 |
Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia (New York, N.Y.). 16: 14-20. PMID 24563616 DOI: 10.1593/Neo.131704 |
0.414 |
|
| 2014 |
Rathkopf DE, Carver BS, Chen Y, Morris MJ, Danila DC, Slovin SF, Autio KA, DeNunzio M, Sawyers CL, Scher HI. Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: TPS5106-TPS5106. DOI: 10.1200/JCO.2014.32.15_SUPPL.TPS5106 |
0.353 |
|
| 2014 |
Vela I, Gao D, Gopalan A, Sboner A, Undvall E, Wanjala J, Iaquinta P, Wongvipat J, Dowling C, Karthaus W, Clevers H, Solomon SB, Beltran H, Kossai M, Mosquera JM, ... ... Sawyers C, et al. MP31-01 DEVELOPMENT OF NOVEL METASTATIC PROSTATE CANCER CELL LINES BY “ORGANOID” IN VITRO CULTURE TECHNOLOGY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.910 |
0.378 |
|
| 2014 |
Blattner M, Lee D, O'Reilly C, Park K, MacDonald T, Khani F, Turner K, Chiu Y, Wild P, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari A, Andren O, et al. MP41-06 SPOP MUTATIONS IN PROSTATE CANCER ACROSS DEMOGRAPHICALLY DIVERSE PATIENT COHORTS. Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1223 |
0.437 |
|
| 2013 |
Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 155: 1309-22. PMID 24315100 DOI: 10.1016/J.Cell.2013.11.012 |
0.322 |
|
| 2013 |
Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, ... ... Sawyers CL, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discovery. 3: 1245-53. PMID 24027196 DOI: 10.1158/2159-8290.Cd-13-0172 |
0.588 |
|
| 2013 |
Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Sawyers CL. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine. 19: 1023-9. PMID 23817021 DOI: 10.1038/Nm.3216 |
0.612 |
|
| 2013 |
Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2: e00499. PMID 23580326 DOI: 10.7554/Elife.00499 |
0.628 |
|
| 2013 |
Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG. β4 Integrin signaling induces expansion of prostate tumor progenitors. The Journal of Clinical Investigation. 123: 682-99. PMID 23348745 DOI: 10.1172/Jci60720 |
0.645 |
|
| 2012 |
Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, Chi H, Greiner DL, Tournier C, Sawyers CL, Flavell RA, Wu H, Davis RJ. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proceedings of the National Academy of Sciences of the United States of America. 109: 12046-51. PMID 22753496 DOI: 10.1073/Pnas.1209660109 |
0.347 |
|
| 2012 |
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, ... ... Sawyers C, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics. 44: 852-60. PMID 22751098 DOI: 10.1038/Ng.2330 |
0.44 |
|
| 2012 |
Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL. Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening Plos One. 7. PMID 22509301 DOI: 10.1371/Journal.Pone.0034414 |
0.339 |
|
| 2012 |
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, ... ... Sawyers CL, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research. 72: 1494-503. PMID 22266222 DOI: 10.1158/0008-5472.Can-11-3948 |
0.627 |
|
| 2012 |
Iaquinta PJ, Wai Chua C, Machado-Pinilla R, Hieronymus H, Wongvipat J, Meier UT, Shen M, Sawyers CL. Abstract PR3: The snoRNP assembly factor SHQ1 is a novel prostate cancer tumor suppressor gene Cancer Research. 72: PR3-PR3. DOI: 10.1158/1538-7445.Prca2012-Pr3 |
0.355 |
|
| 2011 |
Rathkopf DE, Danila DC, Slovin SF, Morris MJ, Steinbrecher JE, Chen Y, Fleisher M, Larson SM, Sawyers CL, Scher HI. A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS190. PMID 28023073 DOI: 10.1200/jco.2011.29.15_suppl.tps190 |
0.317 |
|
| 2011 |
Leder K, Foo J, Skaggs B, Gorre M, Sawyers CL, Michor F. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. Plos One. 6: e27682. PMID 22140458 DOI: 10.1371/Journal.Pone.0027682 |
0.764 |
|
| 2011 |
Paquette RL, Nicoll J, Chalukya M, Elashoff D, Shah NP, Sawyers C, Spiteri E, Nanjangud G, Rao PN. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genetics. 204: 392-7. PMID 21872826 DOI: 10.1016/J.Cancergen.2011.06.002 |
0.444 |
|
| 2011 |
Chen Y, Shamu T, Chen H, Besmer P, Sawyers CL, Chi P. Visualization of the interstitial cells of cajal (ICC) network in mice. Journal of Visualized Experiments : Jove. PMID 21841758 DOI: 10.3791/2802 |
0.549 |
|
| 2011 |
Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. European Urology. 60: 897-904. PMID 21802835 DOI: 10.1016/j.eururo.2011.07.011 |
0.331 |
|
| 2011 |
Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, ... ... Sawyers CL, et al. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Science Translational Medicine. 3: 85ra47. PMID 21632985 DOI: 10.1126/scitranslmed.3002004 |
0.316 |
|
| 2011 |
Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America. 108: 9578-82. PMID 21606347 DOI: 10.1073/pnas.1106383108 |
0.312 |
|
| 2011 |
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19: 575-86. PMID 21575859 DOI: 10.1016/J.Ccr.2011.04.008 |
0.657 |
|
| 2011 |
Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. Plos One. 6: e17449. PMID 21394210 DOI: 10.1371/Journal.Pone.0017449 |
0.354 |
|
| 2011 |
Zhang Y, Hsieh J, Maitra A, Rudin CM, Brekken RA, Sawyers C, Stastny V, Gao B, Frenkel E, Minna JD, Gazdar AF. Abstract 4292: Frequent detection of xenotropic murine leukemia virus (XMLV) strains including XMRV in human cultures established from mouse xenografts Cancer Research. 71: 4292-4292. DOI: 10.1158/1538-7445.Am2011-4292 |
0.305 |
|
| 2010 |
Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 467: 849-53. PMID 20927104 DOI: 10.1038/Nature09409 |
0.63 |
|
| 2010 |
Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 107: 16759-65. PMID 20823238 DOI: 10.1073/pnas.1012443107 |
0.636 |
|
| 2010 |
Chen Y, Sawyers CL. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell. 17: 415-6. PMID 20478521 DOI: 10.1016/j.ccr.2010.04.022 |
0.597 |
|
| 2010 |
Nandana S, Ellwood-Yen K, Sawyers C, Wills M, Weidow B, Case T, Vasioukhin V, Matusik R. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model. The Prostate. 70: 591-600. PMID 19938013 DOI: 10.1002/Pros.21093 |
0.415 |
|
| 2009 |
Mitsiades N, Schultz N, Taylor BS, Hieronymus H, Satagopan J, Scardino PT, Reuter VE, Sander C, Sawyers C, Scher HI. Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5002. PMID 27962896 DOI: 10.1200/Jco.2009.27.15_Suppl.5002 |
0.422 |
|
| 2009 |
King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genetics. 41: 524-6. PMID 19396167 DOI: 10.1038/Ng.371 |
0.36 |
|
| 2009 |
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, ... ... Sawyers CL, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, N.Y.). 324: 787-90. PMID 19359544 DOI: 10.1126/Science.1168175 |
0.625 |
|
| 2009 |
Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research. 69: 958-66. PMID 19176386 DOI: 10.1158/0008-5472.CAN-08-2216 |
0.637 |
|
| 2009 |
Parsons JK, Saria EA, Nakayama M, Vessella RL, Sawyers CL, Isaacs WB, Faith DA, Bova GS, Samathanam CA, Mitchell R, De Marzo AM. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. The Prostate. 69: 559-69. PMID 19142959 DOI: 10.1002/Pros.20904 |
0.323 |
|
| 2009 |
Scher HI, Danila DC, Beer TM, Higano C, Rathkopf D, Taplin M, Efstathiou E, Anand A, Hung D, Hirmand M, Seely L, Larson SM, Fleisher M, Sawyers C. Abstract CN02-03: Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100 Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-Cn02-03 |
0.312 |
|
| 2009 |
Scher HI, Beer T, Higano C, Efstathiou E, Anand A, Hirmand M, Hung D, Steve L, Fleisher M, Sawyers C. CLINICAL STUDY OF MDV3100 IN PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC) Journal of Urology. 181: 230-230. DOI: 10.1016/S0022-5347(09)60655-8 |
0.42 |
|
| 2008 |
Scher HI, Beer TM, Higano CS, Danila DC, Montgomery B, Shelkey J, Hirmand M, Hung D, Sawyers C. Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5006. PMID 27948609 DOI: 10.1200/Jco.2008.26.15_Suppl.5006 |
0.394 |
|
| 2008 |
Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 14: 485-93. PMID 19061839 DOI: 10.1016/J.Ccr.2008.11.001 |
0.323 |
|
| 2008 |
Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Research. 68: 6762-9. PMID 18701501 DOI: 10.1158/0008-5472.Can-08-0107 |
0.324 |
|
| 2008 |
Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, ... Sawyers CL, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 14: 146-55. PMID 18691549 DOI: 10.1016/J.Ccr.2008.06.002 |
0.33 |
|
| 2008 |
Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology. 8: 440-8. PMID 18674639 DOI: 10.1016/j.coph.2008.07.005 |
0.652 |
|
| 2008 |
Duncan EA, Goetz CA, Stein SJ, Mayo KJ, Skaggs BJ, Ziegelbauer K, Sawyers CL, Baldwin AS. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Molecular Cancer Therapeutics. 7: 391-7. PMID 18245668 DOI: 10.1158/1535-7163.Mct-07-0305 |
0.336 |
|
| 2008 |
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, ... ... Sawyers CL, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Medicine. 5: e8. PMID 18215105 DOI: 10.1371/Journal.Pmed.0050008 |
0.613 |
|
| 2008 |
Paquette R, Nicoll J, Chalukya M, Gondek LP, Jasek M, Sawyers C, Shah N, Maciejewski J. Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors Blood. 112: 575-575. DOI: 10.1182/Blood.V112.11.575.575 |
0.333 |
|
| 2007 |
Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency Journal of Clinical Investigation. 117: 2562-2569. PMID 17710227 DOI: 10.1172/Jci30890 |
0.361 |
|
| 2007 |
Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Research. 67: 6083-91. PMID 17616663 DOI: 10.1158/0008-5472.Can-06-4202 |
0.743 |
|
| 2007 |
Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 11: 555-69. PMID 17560336 DOI: 10.1016/J.Ccr.2007.04.021 |
0.754 |
|
| 2007 |
Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 104: 5563-8. PMID 17372210 DOI: 10.1073/pnas.0609139104 |
0.367 |
|
| 2006 |
Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, ... ... Sawyers CL, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine. 3: e485. PMID 17177598 DOI: 10.1371/Journal.Pmed.0030485 |
0.743 |
|
| 2006 |
Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proceedings of the National Academy of Sciences of the United States of America. 103: 19466-71. PMID 17164333 DOI: 10.1073/Pnas.0609239103 |
0.774 |
|
| 2006 |
Ellwood-Yen K, Wongvipat J, Sawyers C. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Research. 66: 10513-6. PMID 17079473 DOI: 10.1158/0008-5472.Can-06-1397 |
0.386 |
|
| 2006 |
Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. 66: 7864-9. PMID 16912159 DOI: 10.1158/0008-5472.Can-04-4392 |
0.754 |
|
| 2006 |
Burgess MR, Sawyers CL. Treating imatinib-resistant leukemia: the next generation targeted therapies. Thescientificworldjournal. 6: 918-30. PMID 16906325 DOI: 10.1100/tsw.2006.184 |
0.378 |
|
| 2006 |
Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 103: 2794-9. PMID 16477019 DOI: 10.1073/Pnas.0510423103 |
0.309 |
|
| 2006 |
Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Research. 66: 1007-14. PMID 16424036 DOI: 10.1158/0008-5472.Can-05-2788 |
0.336 |
|
| 2006 |
Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 107: 2501-6. PMID 16291594 DOI: 10.1182/Blood-2005-07-2966 |
0.768 |
|
| 2006 |
Cortes JE, Kim DW, Rosti G, Rousselot P, Bleickardt E, Zink R, Sawyers C. Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 ‘START-B’ study Journal of Clinical Oncology. 24: 6529-6529. DOI: 10.1200/Jco.2006.24.18_Suppl.6529 |
0.358 |
|
| 2006 |
Shah NP, Skaggs B, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors. Blood. 108: 751-751. DOI: 10.1182/Blood.V108.11.751.751 |
0.344 |
|
| 2006 |
Shah NP, Skaggs B, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy. Blood. 108: 2175-2175. DOI: 10.1182/Blood.V108.11.2175.2175 |
0.383 |
|
| 2006 |
Shah NP, Nicoll JM, Bleickardt E, Nicaise C, Paquette RL, Sawyers CL. Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development. Blood. 108: 2166-2166. DOI: 10.1182/Blood.V108.11.2166.2166 |
0.345 |
|
| 2005 |
Shah N, Sawyers CL, Kantarjian HM, Donato N, Nicoll J, Cortes J, Paquette R, Huang F, Clark E, Talpaz M. Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6521. PMID 27943866 DOI: 10.1200/Jco.2005.23.16_Suppl.6521 |
0.35 |
|
| 2005 |
Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Research. 65: 11565-71. PMID 16357166 DOI: 10.1158/0008-5472.CAN-05-3441 |
0.317 |
|
| 2005 |
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, ... ... Sawyers CL, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/Nejmoa051918 |
0.74 |
|
| 2005 |
Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8253-61. PMID 16278481 DOI: 10.1200/JCO.2005.03.4777 |
0.313 |
|
| 2005 |
Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, et al. Amplification and overexpression of prosaposin in prostate cancer. Genes, Chromosomes & Cancer. 44: 351-64. PMID 16080200 DOI: 10.1002/Gcc.20249 |
0.312 |
|
| 2005 |
Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, ... ... Sawyers CL, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America. 102: 11011-6. PMID 16046538 DOI: 10.1073/Pnas.0504952102 |
0.371 |
|
| 2005 |
Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 435: 1267-70. PMID 15988530 DOI: 10.1038/Nature03669 |
0.344 |
|
| 2005 |
Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proceedings of the National Academy of Sciences of the United States of America. 102: 3395-400. PMID 15705718 DOI: 10.1073/Pnas.0409770102 |
0.36 |
|
| 2005 |
Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 105: 2093-8. PMID 15345592 DOI: 10.1182/Blood-2004-03-1114 |
0.305 |
|
| 2005 |
Skaggs BJ, Burgess MR, Gorre ME, Graeber TG, Sawyers CL. Altered Oncogenic Fitness of Imatinib- and Dasatinib-Resistant BCR-ABL Mutants Is Due to Differential Intrinsic Kinase Activity and Signaling Pathway Selection Defined by Phosphoproteome Profiling. Blood. 106: 692-692. DOI: 10.1182/Blood.V106.11.692.692 |
0.773 |
|
| 2005 |
Branford S, Hughes T, Nicoll J, Paquette R, Bleickardt E, Sawyers C, Shah N. Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients. Blood. 106: 437-437. DOI: 10.1182/Blood.V106.11.437.437 |
0.368 |
|
| 2005 |
Oehler V, Branford S, Pogosova-Agadjanyan E, Shah N, Sawyers C, Mao M, Linsley P, Hughes T, Radich J. Gene Expression Signatures Associated with Treatment and Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients. Blood. 106: 433-433. DOI: 10.1182/Blood.V106.11.433.433 |
0.392 |
|
| 2005 |
Shah NP, Nicoll JM, Branford S, Hughes TP, Paquette RL, Talpaz M, Nicaise C, Huang F, Sawyers CL. Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy. Blood. 106: 1093-1093. DOI: 10.1182/Blood.V106.11.1093.1093 |
0.31 |
|
| 2005 |
SHAH N, NICOLL J, SAWYERS C. Targeted therapy for the treatment of imatinib-resistant chronic myeloid leukemia: A pharmacogenetic analysis Clinical Pharmacology & Therapeutics. 77: P17-P17. DOI: 10.1016/J.Clpt.2004.11.066 |
0.479 |
|
| 2004 |
Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M, Said J, De Kernion J, Reiter RE, Sawyers CL. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8351-6. PMID 15623612 DOI: 10.1158/1078-0432.Ccr-04-0130 |
0.398 |
|
| 2004 |
Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 6: 517-27. PMID 15542435 DOI: 10.1016/J.Ccr.2004.09.031 |
0.761 |
|
| 2004 |
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, N.Y.). 305: 399-401. PMID 15256671 DOI: 10.1126/Science.1099480 |
0.389 |
|
| 2004 |
Shah NP, Lee FY, Sawyers CL, Akin C. BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant. Blood. 104: 797-797. DOI: 10.1182/Blood.V104.11.797.797 |
0.318 |
|
| 2004 |
Gorre ME, Skaggs BJ, Sawyers CL. Imatinib-Resistant BCR-ABL Mutations Alter Oncogenic Potency, Kinase Activity and Substrate Selection. Blood. 104: 556-556. DOI: 10.1182/Blood.V104.11.556.556 |
0.766 |
|
| 2004 |
Burgess MR, Shah NP, Skaggs BJ, Lee FY, Sawyers CL. Comparative Analysis of Two BCR-ABL Small Molecule Inhibitors Reveals Overlapping but Distinct Mechanisms of Resistance. Blood. 104: 552-552. DOI: 10.1182/Blood.V104.11.552.552 |
0.303 |
|
| 2004 |
Chandra J, Tracy J, Gorre M, Talpaz M, Griffin J, Verstovsek S, Beran M, Sawyers C, Sausville E, Kaufmann S. Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance. Blood. 104: 2097-2097. DOI: 10.1182/Blood.V104.11.2097.2097 |
0.771 |
|
| 2003 |
Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias Oncogene. 22: 7389-7395. PMID 14576846 DOI: 10.1038/Sj.Onc.1206942 |
0.336 |
|
| 2003 |
Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 4: 223-38. PMID 14522256 DOI: 10.1016/S1535-6108(03)00197-1 |
0.308 |
|
| 2003 |
Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Research. 63: 2742-6. PMID 12782577 |
0.353 |
|
| 2003 |
Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1267-73. PMID 12684394 |
0.743 |
|
| 2002 |
Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100: 3041-4. PMID 12351420 DOI: 10.1182/Blood-2002-05-1361 |
0.756 |
|
| 2002 |
Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts Cancer Research. 62: 5254-5259. PMID 12234993 |
0.397 |
|
| 2002 |
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2: 117-25. PMID 12204532 DOI: 10.1016/S1535-6108(02)00096-X |
0.756 |
|
| 2002 |
Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of Sciences of the United States of America. 99: 10700-5. PMID 12149456 DOI: 10.1073/Pnas.162140299 |
0.77 |
|
| 2002 |
Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L, Banks L. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene. 21: 5088-96. PMID 12140759 DOI: 10.1038/Sj.Onc.1205668 |
0.73 |
|
| 2002 |
Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell. 1: 413-5. PMID 12124170 DOI: 10.1016/S1535-6108(02)00080-6 |
0.324 |
|
| 2002 |
Gery S, Sawyers CL, Agus DB, Said JW, Koeffler HP. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 21: 4739-46. PMID 12101412 DOI: 10.1038/Sj.Onc.1205142 |
0.317 |
|
| 2002 |
Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews. Cancer. 2: 489-501. PMID 12094235 DOI: 10.1038/Nrc839 |
0.747 |
|
| 2002 |
Sawyers CL. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell. 1: 13-5. PMID 12086882 DOI: 10.1016/S1535-6108(02)00022-3 |
0.358 |
|
| 2002 |
Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Current Opinion in Hematology. 9: 303-7. PMID 12042704 DOI: 10.1097/00062752-200207000-00007 |
0.726 |
|
| 2002 |
Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Molecular and Cellular Biology. 22: 2862-70. PMID 11909978 DOI: 10.1128/MCB.22.8.2862-2870.2002 |
0.331 |
|
| 2002 |
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. The New England Journal of Medicine. 346: 645-52. PMID 11870241 DOI: 10.1056/Nejmoa011573 |
0.341 |
|
| 2002 |
Sawyers CL. Rational therapeutic intervention in cancer: kinases as drug targets. Current Opinion in Genetics & Development. 12: 111-5. PMID 11790564 DOI: 10.1016/S0959-437X(01)00273-8 |
0.335 |
|
| 2002 |
Sawyers CL. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Seminars in Hematology. 38: 15-21. PMID 11526597 DOI: 10.1016/S0037-1963(01)90113-1 |
0.349 |
|
| 2001 |
Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America. 98: 10314-9. PMID 11504908 DOI: 10.1073/Pnas.171076798 |
0.818 |
|
| 2001 |
Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, ... Sawyers C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proceedings of the National Academy of Sciences of the United States of America. 98: 10320-5. PMID 11504907 DOI: 10.1073/Pnas.171060098 |
0.803 |
|
| 2001 |
Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, Tomonaga M, Sawyers C, Said JW, Koeffler HP. Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene. 20: 3301-5. PMID 11423979 DOI: 10.1038/Sj.Onc.1204421 |
0.429 |
|
| 2001 |
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, N.Y.). 293: 876-80. PMID 11423618 DOI: 10.1126/Science.1062538 |
0.764 |
|
| 2001 |
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine. 344: 1031-7. PMID 11287972 DOI: 10.1056/Nejm200104053441401 |
0.303 |
|
| 2000 |
Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, Whang YE. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proceedings of the National Academy of Sciences of the United States of America. 97: 4233-8. PMID 10760291 DOI: 10.1073/Pnas.97.8.4233 |
0.76 |
|
| 2000 |
Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Molecular and Cellular Biology. 20: 1179-86. PMID 10648603 DOI: 10.1128/Mcb.20.4.1179-1186.2000 |
0.799 |
|
| 2000 |
Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Sawyers CL. Bcr-abl kinase inhibition as the basis of therapy for cml Experimental Hematology. 28: 130. DOI: 10.1016/S0301-472X(00)00503-8 |
0.318 |
|
| 1999 |
Huang W, Shostak Y, Tarr P, Sawyers C, Carey M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. The Journal of Biological Chemistry. 274: 25756-68. PMID 10464314 DOI: 10.1074/Jbc.274.36.25756 |
0.379 |
|
| 1999 |
Craft N, Sawyers CL. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Reviews. 17: 421-7. PMID 10453286 DOI: 10.1023/A:1006141806801 |
0.671 |
|
| 1999 |
Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Molecular and Cellular Biology. 19: 5143-54. PMID 10373563 DOI: 10.1128/Mcb.19.7.5143 |
0.706 |
|
| 1999 |
Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine. 5: 280-5. PMID 10086382 DOI: 10.1038/6495 |
0.699 |
|
| 1999 |
Reiter RE, Yamashiro J, Sawyers C, Loda M, Witte ON. A Type Ii Transmembrane Glycoprotein Associated With Osteogenesis Can Accelerate Androgen-Independent Prostate Cancer Progression In Vivo The Journal of Urology. 128. DOI: 10.1097/00005392-199904010-00516 |
0.556 |
|
| 1998 |
Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proceedings of the National Academy of Sciences of the United States of America. 95: 15587-91. PMID 9861013 DOI: 10.1073/Pnas.95.26.15587 |
0.825 |
|
| 1998 |
Senechal K, Heaney C, Druker B, Sawyers CL. Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Molecular and Cellular Biology. 18: 5082-90. PMID 9710592 DOI: 10.1128/Mcb.18.9.5082 |
0.334 |
|
| 1998 |
Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proceedings of the National Academy of Sciences of the United States of America. 95: 5246-50. PMID 9560261 DOI: 10.1073/Pnas.95.9.5246 |
0.349 |
|
| 1998 |
Xu F, Sharma S, Gardner A, Tu Y, Raitano A, Sawyers C, Lichtenstein A. Interleukin-6–Induced Inhibition of Multiple Myeloma Cell Apoptosis: Support for the Hypothesis That Protection Is Mediated Via Inhibition of the JNK/SAPK Pathway Blood. 92: 241-251. DOI: 10.1182/Blood.V92.1.241.413K28_241_251 |
0.328 |
|
| 1997 |
Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Bailliere's Clinical Haematology. 10: 223-31. PMID 9376661 DOI: 10.1016/S0950-3536(97)80004-2 |
0.308 |
|
| 1997 |
Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (New York, N.Y.). 277: 693-6. PMID 9235893 DOI: 10.1126/Science.277.5326.693 |
0.327 |
|
| 1997 |
Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Medicine. 3: 402-8. PMID 9095173 DOI: 10.1038/Nm0497-402 |
0.52 |
|
| 1997 |
Senechal K, Sawyers CL. Signal transduction-based strategies for the treatment of chronic myelogenous leukemia. Molecular Medicine Today. 2: 503-9. PMID 9015791 DOI: 10.1016/S1357-4310(97)81454-2 |
0.312 |
|
| 1996 |
Yuan ZM, Huang Y, Fan MM, Sawyers C, Kharbanda S, Kufe D. Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53. The Journal of Biological Chemistry. 271: 26457-60. PMID 8900110 DOI: 10.1074/Jbc.271.43.26457 |
0.349 |
|
| 1996 |
Yuan ZM, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S, Kufe D. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature. 382: 272-4. PMID 8717045 DOI: 10.1038/382272A0 |
0.359 |
|
| 1995 |
Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proceedings of the National Academy of Sciences of the United States of America. 92: 11746-50. PMID 8524841 DOI: 10.1073/PNAS.92.25.11746 |
0.328 |
|
| 1995 |
Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene Journal of Experimental Medicine. 181: 307-313. PMID 7807010 DOI: 10.1084/Jem.181.1.307 |
0.421 |
|
| 1994 |
Sawyers CL, Denny CT. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell. 77: 171-3. PMID 8168126 DOI: 10.1016/0092-8674(94)90307-7 |
0.324 |
|
| 1994 |
Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc Science. 264: 424-426. PMID 8153630 DOI: 10.1126/Science.8153630 |
0.512 |
|
| 1994 |
Sawyers CL. Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia. Leukemia & Lymphoma. 101-3. PMID 8124222 DOI: 10.3109/10428199309064268 |
0.303 |
|
| 1994 |
Orr SL, Hughes TP, Sawyers CL, Kato RM, Quan SG, Williams SP, Witte ON, Hood L. Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination. Proceedings of the National Academy of Sciences of the United States of America. 91: 11869-73. PMID 7991548 DOI: 10.1073/Pnas.91.25.11869 |
0.399 |
|
| 1994 |
Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth Cell. 77: 121-131. PMID 7512450 DOI: 10.1016/0092-8674(94)90240-2 |
0.522 |
|
| 1992 |
Sawyers CL, Gishizky ML, Quan S, Golde DW, Witte ON. Propagation of human elastic myeloid leukemias in the SCID mouse Blood. 79: 2089-2098. PMID 1562735 DOI: 10.1182/Blood.V79.8.2089.Bloodjournal7982089 |
0.492 |
|
| 1992 |
Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes Cell. 70: 901-910. PMID 1525828 DOI: 10.1016/0092-8674(92)90241-4 |
0.451 |
|
| 1991 |
Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis Cell. 64: 337-350. PMID 1988151 DOI: 10.1016/0092-8674(91)90643-D |
0.45 |
|
| 1990 |
Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America. 87: 563-7. PMID 2405384 DOI: 10.1073/Pnas.87.2.563 |
0.388 |
|
| Show low-probability matches. |